Prognostic impact of lymphadenectomy in uterine clear cell carcinoma

por Mahdi, Haider, Lockhart, David, Moselmi-Kebria, Mehdi
Publicado 2015

Adverse post-operative outcomes in Jehovah's witnesses with gynecologic cancer within 30 days of surgery: A single institution review of 36 cases()

por Moulton, Laura J., Rose, Peter G., Mahdi, Haider
Publicado 2017

Targeting regulatory T cells by E7777 enhances CD8 T-cell–mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models

por Mahdi, Haider S., Woodall-Jappe, Mary, Singh, Preeti, Czuczman, Myron S.
Publicado 2023

Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions

por Maurer, Kathryn, Michener, Chad, Mahdi, Haider, Rose, Peter G.
Publicado 2017

Lymph node metastasis and pattern of recurrence in clinically early stage endometrial cancer with positive lymphovascular space invasion

por Mahdi, Haider, Jernigan, Amelia, Nutter, Benjamin, Michener, Chad, Rose, Peter G.
Publicado 2015

Genomic analyses of high‐grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities

por Mahdi, Haider, Joehlin‐Price, Amy, Elishaev, Esther, Dowlati, Afshin, Abbas, Ata
Publicado 2021

The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone

por Mahdi, Haider, Nutter, Benjamin, Abdul-Karim, Fadi, Amarnath, Sudha, Rose, Peter G
Publicado 2016

Clinical trials and progress with paclitaxel in ovarian cancer

por Kumar, Sanjeev, Mahdi, Haider, Bryant, Christopher, Shah, Jay P, Garg, Gunjal, Munkarah, Adnan
Publicado 2010

Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?

por Mahdi, Haider, Ray-Coquard, Isabelle, Lorusso, Domenica, Mirza, Mansoor Raza, Monk, Bradley J, Slomovitz, Brian
Publicado 2023

Predictors of response to immune checkpoint inhibition in a real world gynecologic cancer population()

por Kuznicki, Michelle L., Bennett, Carrie, Yao, Meng, Joehlin-Price, Amy, Rose, Peter G., Mahdi, Haider
Publicado 2020

Case Report: Circulating Tumor DNA Fraction Analysis Using Ultra-Low-Pass Whole-Genome Sequencing Correlates Response to Chemoradiation and Recurrence in Stage IV Small-Cell Carcin...

por Abbas, Ata, Gruner, Morgan, Karohl, Jennifer, Rose, Peter G., Joehlin-Price, Amy, Stover, Daniel, Mahdi, Haider
Publicado 2021

High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition

por Ni, Ying, Soliman, Ahmed, Joehlin-Price, Amy, Rose, Peter G., Vlad, Anda, Edwards, Robert P., Mahdi, Haider
Publicado 2021

The Role of Frozen Section in Surgical Staging of Low Risk Endometrial Cancer

por Kumar, Sanjeev, Bandyopadhyay, Sudeshna, Semaan, Assaad, Shah, Jay P., Mahdi, Haider, Morris, Robert, Munkarah, Adnan, Ali-Fehmi, Rouba
Publicado 2011

Computational image features of immune architecture is associated with clinical benefit and survival in gynecological cancers across treatment modalities

por Azarianpour, Sepideh, Corredor, Germán, Bera, Kaustav, Leo, Patrick, Fu, Pingfu, Toro, Paula, Joehlin-Price, Amy, Mokhtari, Mojgan, Mahdi, Haider, Madabhushi, Anant
Publicado 2022

Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression

por Pavicic, Paul G., Rayman, Patricia A., Swaidani, Shadi, Rupani, Amit, Makarov, Vladimir, Tannenbaum, Charles S., Edwards, Robert P., Vlad, Anda M., Diaz-Montero, C. Marcela, Mahdi, Haider
Publicado 2023

Genetic Counseling and Germline Testing in the Era of Tumor Sequencing: A Cohort Study

por Klek, Stefan, Heald, Brandie, Milinovich, Alex, Ni, Ying, Abraham, Jame, Mahdi, Haider, Estfan, Bassam, Khorana, Alok A, Bolwell, Brian J, Grivas, Petros, Sohal, Davendra P S, Funchain, Pauline
Publicado 2020

Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition

por Al-Sudani, Hussein, Ni, Ying, Jones, Philip, Karakilic, Huseyin, Cui, Lei, Johnson, Lisa D. S., Rose, Peter G., Olawaiye, Alexander, Edwards, Robert P., Uger, Robert A., Lin, Gloria H. Y., Mahdi, Haider
Publicado 2023

Cancer-associated MSC drive tumor immune exclusion and resistance to immunotherapy, which can be overcome by Hedgehog inhibition

por Cascio, Sandra, Chandler, Chelsea, Zhang, Linan, Sinno, Sarah, Gao, Bingsi, Onkar, Sayali, Bruno, Tullia C., Vignali, Dario A. A., Mahdi, Haider, Osmanbeyoglu, Hatice U., Vlad, Anda M., Coffman, Lan G., Buckanovich, Ronald J.
Publicado 2021

Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors

por Wang, Xiangxue, Barrera, Cristian, Bera, Kaustav, Viswanathan, Vidya Sankar, Azarianpour-Esfahani, Sepideh, Koyuncu, Can, Velu, Priya, Feldman, Michael D., Yang, Michael, Fu, Pingfu, Schalper, Kurt A., Mahdi, Haider, Lu, Cheng, Velcheti, Vamsidhar, Madabhushi, Anant
Publicado 2022

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)

por Mahdi, Haider, Hafez, Navid, Doroshow, Deborah, Sohal, Davendra, Keedy, Vickie, Do, Khanh T., LoRusso, Patricia, Jürgensmeier, Juliane, Avedissian, Manuel, Sklar, Jeffrey, Glover, Colin, Felicetti, Brunella, Dean, Emma, Mortimer, Peter, Shapiro, Geoffrey I., Eder, Joseph Paul
Publicado 2021